1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Clinical Microbiology Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing use of clinical microbiology in managing and controlling infectious diseases
5.1.1.2. Favorable government and private organizations support, and initiatives in cancer diagnosis and research
5.1.2. Restraints
5.1.2.1. Limited availability of skilled professionals, equipment and infrastructure
5.1.3. Opportunities
5.1.3.1. Technological advancement in clinical microbiology products and processes
5.1.3.2. Introduction of point-of-care microbiology testing
5.1.4. Challenges
5.1.4.1. Problems concerning quality assurance and management in clinical microbiology laboratories
5.2. Market Segmentation Analysis
5.2.1. Product: Use of laboratory instruments in clinical microbiology assessments
5.2.2. Specimen Type: Preference for serum samples in serological testing to detect past or current infections
5.2.3. End-User: Adoption of clinical microbiology in laboratories and research institutes to provide detailed insights about infectious disease conditions
5.2.4. Application: Increasing use of clinical microbiology to diagnose gastrointestinal (GI) diseases by identifying causative pathogens
5.3. Market Trend Analysis
5.3.1. Presence of well-established market vendors with the ongoing development of advanced clinical microbiology testings
5.3.2. Prevalence of infectious disease and improvements in clinical microbiology products in APAC
5.3.3. Supportive government initiatives and ongoing research to overcome the burden of infectious diseases in the EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Clinical Microbiology Market, by Product
6.1. Introduction
6.2. Instruments
6.3. Reagents
7. Clinical Microbiology Market, by Specimen Type
7.1. Introduction
7.2. Blood
7.3. Body fluids
7.4. Cerebrospinal Spinal Fluid
7.5. Fecal
7.6. Saliva
7.7. Serum
7.8. Synovial Fluid
7.9. Urine
8. Clinical Microbiology Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Hospitals & Care Providers
8.4. Laboratories
9. Clinical Microbiology Market, by Application
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Cardiology
9.4. Diabetes
9.5. Drug Testing
9.6. Gastrointestinal Diseases
9.7. Nephrology
9.8. Oncology
9.9. Periodontal Diseases
9.10. Respiratory Diseases
9.11. Sexually Transmitted Diseases
10. Americas Clinical Microbiology Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Clinical Microbiology Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Clinical Microbiology Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Sci-Tech Daresbury’s Perfectus Biomed Group Acquired by Global Medical Device Testing Leader NAMSA.
13.3.1.2. ValitaCell Joins Beckman Coulter Life Sciences.
13.3.1.3. Global Access Diagnostics Acquires Manufacturing Rights for IT-LEISH Rapid Diagnostic Test From Bio-Rad Laboratories.
13.3.1.4. SSI Diagnostica Continues a Strong Growth Journey.
13.3.1.5. DCN Dx Acquires Microbiological Testing Products Company Biomed Diagnostics.
13.3.1.6. bioMérieux Strengthens its Commitment to Fight Antimicrobial Resistance with the Acquisition of Specific Diagnostics, An Innovative Company Focusing on Fast AST Solutions.
13.3.1.7. Raue Advises Sonic Healthcare on the Acquisition of Diagnosticum Laboratory Group.
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Transformative Agreement Signed Between The Microbiology Society And Indian Institute Of Science Bangalore
13.3.2.2. Hardy Diagnostics Awarded Manual Microbiology Agreement With Premier, Inc.
13.3.2.3. Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Viral and Bacterial Infections.
13.3.2.4. FASTinov Collaborates with Beckman Coulter Life Sciences to Bring Ultra-Rapid 2h-AST Disruptive Technology to Clinical Microbiology Laboratories.
13.3.2.5. BD, Accelerate Diagnostics Announce Global Commercial Collaboration.
13.3.2.6. ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN.
13.3.3. New Product Launch & Enhancement
13.3.3.1. MAESTRIA, A New Generation Microbiology Middleware Developed by Biomérieux to Optimize Laboratory Workflow and Improve Patient Care.
13.3.3.2. BD Introduces Fully Automated Robotic Track System for Microbiology Labs.
13.3.3.3. Bio-Rad Expands QC Range for Abbott Diagnostic Platforms.
13.3.3.4. HORIBA Veterinary Adds New Rapid PCR Test for Difficult to Diagnose Parasite.
13.3.3.5. Hardy Diagnostics Now Offers the BioCode MDx-3000.
13.3.3.6. COPAN Diagnostics Announces Another Giant Step in the Evolution of Artificial Intelligence in Clinical Microbiology.
13.3.4. Investment & Funding
13.3.4.1. Cambridge Start-Up Won Funding To Develop New Diagnostics.
13.3.4.2. Department of Medical Microbiology Unveils Four New Projects Worth USD 6.8 Million and New Website.
13.3.4.3. ASM Funded for Inclusive Microbiology Leaders Program.
13.3.4.4. Federal Funds Set To Boost U of A’s Ability To Handle Highly Infectious Pathogens.
13.3.4.5. Oxford Gets £122m (USD 136.63 Million) Funding for Healthcare Research.
13.3.4.6. Israel: EUR 22 Million (Usd 24.26 Million) EU Backing for Israeli Microbiology Diagnostic Player Pocared.
13.3.4.7. NIH Funded New Tuberculosis Research Advancement Centers.
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Wichita State’s MDL Lab Shifting To Microbiology.
13.3.5.2. Upstate Planned To Launch A Multidisciplinary Lyme And Tick-Borne Disease Treatment Center.
13.3.5.3. SGS Launched New Microbiology Laboratory In Phoenix, Arizona.
13.3.5.4. Merck Announced Organizational Transformation of Life Science Business Sector To Strengthen Cdmo Offering And Accelerate Future Growth.
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. 3M Company
14.1.2. Abbott Laboratories
14.1.3. Advanced Instruments, LLC
14.1.4. Agilent Technologies, Inc.
14.1.5. B. Braun SE
14.1.6. Beckman Coulter, Inc.
14.1.7. Becton, Dickinson and Company
14.1.8. Bio-Rad Laboratories, Inc.
14.1.9. bioMérieux S.A.
14.1.10. Cardinal Health, Inc.
14.1.11. Clinichem Ltd.
14.1.12. COPAN Diagnostics Inc.
14.1.13. Diagnóstica Longwood S.L.
14.1.14. ELITech Group
14.1.15. F. Hoffmann-La Roche Ltd.
14.1.16. Hardy Diagnostics
14.1.17. HORIBA, Ltd.
14.1.18. Kyokuto Pharmaceutical Industrial Co., Ltd.
14.1.19. Laboratorios Conda, S.A.
14.1.20. Liofilchem S.r.l.
14.1.21. Merck KGaA
14.1.22. Prestige Diagnostics U.K. Ltd.
14.1.23. Pro Lab Diagnostics Inc.
14.1.24. QIAGEN N.V.
14.1.25. Rapid Micro Biosystems, Inc.
14.1.26. Shimadzu Corporation
14.1.27. SSI Diagnostica A/S
14.1.28. TCS Biosciences Ltd.
14.1.29. Thermo Fisher Scientific Inc.
14.1.30. Vircell S.L.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing